Dr.ย Wee Jooย Chng
MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS
Senior Consultant, Division of Haematology
corporate_fareNational University Cancer Institute, Singapore
Wee Joo Chng
MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS
Professor Wee Joo Chng is a Senior Consultant in the Division of Haematology at the National University Cancer Institute, Singapore (NCIS), and holds the distinguished Yong Loo Lin Professorship in Medical Oncology at the National University of Singapore. He is one of Singapore's most recognised haematology specialists, with a clinical and research focus on multiple myeloma, lymphoma, and haematologic malignancies.
Over a career spanning more than two decades at NCIS, Prof. Chng has built a reputation for integrating translational genomics research directly into clinical practice. His work employs global genomic platforms โ including microarray and next-generation sequencing โ to understand disease heterogeneity in multiple myeloma, lymphoma, and acute myeloid leukaemia, with the goal of improving risk stratification and personalised treatment planning. He serves concurrently as Executive Director of the Singapore Translational Cancer Consortium, Vice President for Biomedical Sciences Research at NUS, and Group Chief Scientist at NUHS. His Google Scholar profile records more than 48,000 citations and an h-index of 96. He is Chairperson of the Asian Myeloma Network Executive Committee and a recipient of the International Myeloma Foundation's Brian G.M. Durie Outstanding Achievement Award.
CancerFax can coordinate medical-record review and consultation support for international patients seeking access to Prof. Chng's expertise at NCIS.
Why Consider Prof. Wee Joo Chng?
Prof. Chng combines over two decades of specialist haematology practice with world-class translational research in multiple myeloma and lymphoma, making him a leading choice for patients seeking expert evaluation of complex blood cancers at a major academic cancer centre.
Areas of Specialisation
Expert haematology care with a focus on multiple myeloma, lymphoma, and genomics-driven treatment planning
Prof. Chng's clinical and research work centres on haematologic malignancies, with particular depth in multiple myeloma and lymphoma. His approach integrates molecular and genomic profiling to guide risk assessment and therapy selection.
Multiple Myeloma
One of Prof. Chng's two officially listed special interests; a primary focus of clinical care and translational research.
- arrow_rightGenomic risk classification in multiple myeloma
- arrow_rightInternational Myeloma Working Group risk-stratification frameworks
- arrow_rightBiomarker-guided assessment for treatment selection
- arrow_rightNovel agent combinations for newly diagnosed and relapsed myeloma
- arrow_rightResearch into immunomodulatory drug resistance and proteasome inhibitor resistance
- arrow_rightPrecision therapy approaches informed by molecular disease features
Lymphoma
Listed as a special interest alongside multiple myeloma; integral to Prof. Chng's haematology-oncology practice at NCIS.
- arrow_rightDiagnosis and clinical management of lymphoid malignancies
- arrow_rightGenomic characterisation of lymphoma subtypes
- arrow_rightMultidisciplinary care coordination at NCIS
Haematologic Malignancies & Genomics
Broader research and clinical expertise spanning acute myeloid leukaemia and other blood cancers, underpinned by genomic science.
- arrow_rightGenomic studies to understand disease heterogeneity in AML
- arrow_rightIdentification of prognostic markers and therapeutic targets
- arrow_rightApplication of microarray and next-generation sequencing platforms
- arrow_rightGenomics-driven treatment target identification across haematologic cancers
Procedures & Clinical Services
Haematology-oncology consultation, molecular-guided treatment planning, and translational research support
Prof. Chng provides specialist haematology consultation and evidence-based treatment planning for patients with multiple myeloma, lymphoma, and other blood cancers. His services are embedded within the multidisciplinary framework of NCIS.
Haematology-Oncology Consultation
Medical OncologyComprehensive specialist consultation for haematologic malignancies including multiple myeloma, lymphoma, and leukaemia.
Molecular & Genomic Assessment
DiagnosisApplication of genomic profiling tools to characterise disease biology and inform precision treatment decisions.
Second Opinion โ Blood Cancers
Second OpinionExpert second opinion for patients with complex or relapsed haematologic malignancies, including myeloma and lymphoma.
Monitoring & Treatment Response Assessment
MonitoringOngoing evaluation of treatment response, disease progression, and management adjustments in myeloma and lymphoma patients.
Research & Publications
Translational haematology research across multiple myeloma, lymphoma, and blood cancers
Prof. Chng is one of the most cited researchers in haematologic malignancies globally. His work spans genomic characterisation of blood cancers, drug resistance mechanisms, risk stratification, and precision medicine.
Prof. Chng's publication record in multiple myeloma and haematologic malignancies spans more than 48,000 citations with an h-index of 96, as listed on Google Scholar.
Education & Training
Prof. Chng completed his medical training in the United Kingdom before returning to Singapore for haematology specialisation and doctoral studies. An A*STAR international fellowship took him to Mayo Clinic for multiple myeloma genetics research.
Clinical Experience
Prof. Chng has served as Senior Consultant in the Division of Haematology at NCIS for over two decades, combining active clinical practice with leadership roles across research, academia, and Singapore's national cancer research infrastructure.
Languages & International
Prof. Chng consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting in languages beyond English and Mandarin.
CancerFax can coordinate professional medical interpreter support for international patients where required.
How CancerFax Helps You Access Dr. Wee Joo Chng
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Wee Joo Chng's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Wee Joo Chng's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Wee Joo Chng before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Wee Joo Chng's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Wee Joo Chng's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Wee Joo Chng's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Wee Joo Chng
Prof. Chng is a specialist haematologist with officially listed special interests in multiple myeloma and lymphoma. His broader clinical and research work also covers acute myeloid leukaemia and other haematologic malignancies at the National University Cancer Institute, Singapore.
Prof. Chng is based at the National University Cancer Institute, Singapore (NCIS), where he serves as Senior Consultant in the Division of Haematology, Department of Haematology-Oncology. NCIS is part of the National University Health System (NUHS).
CancerFax can coordinate medical-record review and consultation support for international patients seeking access to Prof. Chng's expertise at NCIS, subject to hospital availability and individual case acceptance. Please submit your reports through CancerFax to begin the process.
You can submit your medical reports โ including pathology, imaging, molecular test results, and prior treatment history โ through CancerFax. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with NCIS, subject to availability and case acceptance.
Prof. Chng's research uses global genomic technologies, including microarray and next-generation sequencing, to study the molecular and clinical heterogeneity of haematologic malignancies โ particularly multiple myeloma, lymphoma, and acute myeloid leukaemia. His work aims to identify prognostic markers, therapeutic targets, and mechanisms of drug resistance. He has accumulated over 48,000 citations with an h-index of 96, as listed on Google Scholar.
Prof. Chng has received multiple prestigious awards, including the International Myeloma Foundation's Brian G.M. Durie Outstanding Achievement Award, the National Medical Excellence Outstanding Clinician Scientist Award, and the National Medical Research Council Senior Translational Research Award, among others. He also serves as Chairperson of the Asian Myeloma Network Executive Committee.
Connect with Wee Joo Chng Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.